KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) Research & Development: 2017-2024

Historic Research & Development for Aquestive Therapeutics (AQST) over the last 8 years, with Dec 2024 value amounting to $20.3 million.

  • Aquestive Therapeutics' Research & Development fell 14.03% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.9 million, marking a year-over-year increase of 3.63%. This contributed to the annual value of $20.3 million for FY2024, which is 54.76% up from last year.
  • As of FY2024, Aquestive Therapeutics' Research & Development stood at $20.3 million, which was up 54.76% from $13.1 million recorded in FY2023.
  • In the past 5 years, Aquestive Therapeutics' Research & Development registered a high of $20.3 million during FY2024, and its lowest value of $13.1 million during FY2023.
  • Moreover, its 3-year median value for Research & Development was $17.5 million (2022), whereas its average is $17.0 million.
  • As far as peak fluctuations go, Aquestive Therapeutics' Research & Development dropped by 25.04% in 2023, and later soared by 54.76% in 2024.
  • Yearly analysis of 5 years shows Aquestive Therapeutics' Research & Development stood at $19.9 million in 2020, then fell by 14.28% to $17.0 million in 2021, then climbed by 2.55% to $17.5 million in 2022, then dropped by 25.04% to $13.1 million in 2023, then spiked by 54.76% to $20.3 million in 2024.